This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.

The purpose of this study is to assess the long-term safety and tolerability of [S,S]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.

Inclusion Criteria:

• Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial.
• Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

Exclusion Criteria:

• Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator.
• Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.